Different treatment strategies and molecular features between right-sided and left-sided colon cancers

World Journal of Gastroenterology

Volumn 21, Issue 21, 2015, Pages 6470-6478

  Shen, Hong ^a   Yang, Jiao ^a   Huang, Qing ^a   Jiang, Meng Jie ^a   Tan, Yi Nuo ^a   Fu, Jian Fei ^a   Zhu, Li Zhen ^a   Fang, Xue Feng ^a   Yuan, Ying ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colon cancer; Left; Molecular; Right; Survival

Indexed keywords

ANNEXIN; B RAF KINASE; BEVACIZUMAB; CELL CYCLE PROTEIN; CETUXIMAB; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; IRINOTECAN; K RAS PROTEIN; MICRORNA 1288; MICRORNA 146A; MICRORNA 147B; MICRORNA 31; MOLECULAR MARKER; OXALIPLATIN; PROTEIN ANXA10; PROTEIN P53; PYRUVATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 3; WNT PROTEIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACETYLATOR PHENOTYPE; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; ASCENDING COLON; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHROMOSOMAL INSTABILITY; CLINICAL FEATURE; COLON CANCER; COLON CARCINOGENESIS; COLON METASTASIS; COLON RESECTION; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DESCENDING COLON; DISEASE FREE SURVIVAL; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LEFT COLON CANCER; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PHENOTYPE; RIGHT COLON CANCER; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CHEMISTRY; COLONIC NEOPLASMS; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PATHOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930811951     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i21.6470     Document Type: Article

References (56)

1. Xiang L, Zhan Q, Zhao XH, Wang YD, An SL, Xu YZ, Li AM, Gong W, Bai Y, Zhi FC, Liu SD. Risk factors associated with missed colorectal flat adenoma: a multicenter retrospective tandem colonoscopy study. World J Gastroenterol 2014; 20: 10927-10937 [PMID: 25152596 DOI: 10.3748/wjg.v20.i31.10927]
2. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53: 57-64 [PMID: 20010352 DOI: 10.1007/DCR.0b013e3181c703a4]
3. Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, Kitagawa Y. Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution. Surg Today 2014; 44: 1685-1691 [PMID: 24126535 DOI: 10.1007/s00595-013-0748-5]
4. Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988; 31: 33-41 [PMID: 3366023]
5. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 2008; 15: 2388-2394 [PMID: 18622647 DOI: 10.1245/s10434-008-0015-y]
6. Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO, Loconte NK, Greenberg CC, Smith MA. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol 2014; 21: 1781-1791 [PMID: 24643898 DOI: 10.1245/s10434-014-3631-8]
7. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-1750 [PMID: 10832824 DOI: 10.1016/s0140-6736(00)02261-3]
8. Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25: 1995-2001 [PMID: 25057166 DOI: 10.1093/annonc/mdu275]
9. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013; 31: 3664-3672 [PMID: 24019539 DOI: 10.1200/jco.2013.48.9591]
10. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 2014; 20: 3033-3043 [PMID: 24687927 DOI: 10.1158/1078-0432.ccr-13-3140]
11. Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 2014; 25: 2378-2385 [PMID: 25294886 DOI: 10.1093/annonc/mdu464]
12. Price TJ, Beeke C, Ullah S, Padbury R, Maddern G, Roder D, Townsend AR, Moore J, Roy A, Tomita Y, Karapetis C. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer 2015; 121: 830-835 [PMID: 25377235 DOI: 10.1002/cncr.29129]
13. Suttie SA, Shaikh I, Mullen R, Amin AI, Daniel T, Yalamarthi S. Outcome of right- and left-sided colonic and rectal cancer following surgical resection. Colorectal Dis 2011; 13: 884-889 [PMID: 20594201 DOI: 10.1111/j.1463-1318.2010.02356.x]
14. Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs 2014; 25: 212-218 [PMID: 24201305 DOI: 10.1097/CAD.0000000000000041]
15. von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, Kirchner T, Haas M, Holch J, Michl M, Aubele P, Boeck S, Schulz C, Giessen C, Stintzing S, Modest DP. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014; 140: 1607-1614 [PMID: 24816724 DOI: 10.1007/s00432-014-1678-3]
16. Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; Epub ahead of print [PMID: 25979833]
17. Missiaglia E, Jacobs B, Di Narzo AF, Soneson C, Roth A, Bosman F, d'Ario G, Klingbiel D, Yan P, Delorenzi M, Tejpar S. Proximal and distal colon tumors as distinct biologic entities with different prognoses. 2013 ASCO Annual Meeting Abstract. J Clin Oncol 2013; 31 suppl: 3526
18. Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013; 24: 2554-2559 [PMID: 23864097 DOI: 10.1093/annonc/mdt253]
19. Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J 2015; 15: 69-76 [PMID: 25069475 DOI: 10.1038/tpj.2014.40]
20. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 2003; 12: 755-762 [PMID: 12917207]
21. Priolli DG, Abrantes AM, Neves S, Gonçalves AC, Lopes CO, Martinez NP, Cardinalli IA, Ribeiro AB, Botelho MF. Microenvironment influence on human colon adenocarcinoma phenotypes and matrix metalloproteinase-2, p53 and β-catenin tumor expressions from identical monoclonal cell tumor in the orthotopic model in athymic nude rats. Scand J Gastroenterol 2014; 49: 309-316 [PMID: 24325610 DOI: 10.3109/00365521.2013.869350]
22. Gervaz P, Cerottini JP, Bouzourene H, Hahnloser D, Doan CL, Benhattar J, Chaubert P, Secic M, Gillet M, Carethers JM. Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. Surgery 2002; 131: 190-197 [PMID: 11854698]
23. Shin US, Cho SS, Moon SM, Park SH, Jee SH, Jung EJ, Hwang DY. Is microsatellite instability really a good prognostic factor of colorectal cancer? Ann Coloproctol 2014; 30: 28-34 [PMID: 24639968 DOI: 10.3393/ac.2014.30.1.28]
24. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, Smith EJ, Lee M, Janke R, Ngo T, Tejada R, Ji M, Kinseth M, Cabrera BL, Miyai K, Keku TO, Martin CF, Galanko JA, Sandler RS, McGuire KL. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS One 2014; 9: e100461 [PMID: 24956473 DOI: 10.1371/journal.pone.0100461]
25. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114 [PMID: 21641636 DOI: 10.1016/s0140-6736(11)60613-2]
26. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226 [PMID: 20498393 DOI: 10.1200/jco.2009.27.1825]
27. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-8546 [PMID: 18922929 DOI: 10.1158/0008-5472.can-08-1171]
28. Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol 2014; 25: 2314-2327 [PMID: 24718889 DOI: 10.1093/annonc/mdu149]
29. Ahmed FE. miRNA as markers for the diagnostic screening of colon cancer. Expert Rev Anticancer Ther 2014; 14: 463-485 [PMID: 24580550]
30. Dawson H, Galván JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A, Zlobec I. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer 2014; 134: 2342-2351 [PMID: 24166180 DOI: 10.1002/ijc.28564]
31. Kaz AM, Wong CJ, Dzieciatkowski S, Luo Y, Schoen RE, Grady WM. Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics 2014; 9: 492-502 [PMID: 24413027 DOI: 10.4161/epi.27650]
32. Koestler DC, Li J, Baron JA, Tsongalis GJ, Butterly LF, Goodrich M, Lesseur C, Karagas MR, Marsit CJ, Moore JH, Andrew AS, Srivastava A. Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Mod Pathol 2014; 27: 145-155 [PMID: 23868178 DOI: 10.1038/modpathol.2013.104]
33. Ogura T, Kakuta M, Yatsuoka T, Nishimura Y, Sakamoto H, Yamaguchi K, Tanabe M, Tanaka Y, Akagi K. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. Oncol Rep 2014; 32: 50-56 [PMID: 24806883 DOI: 10.3892/or.2014.3165]
34. Siraj AK, Bu R, Prabhakaran S, Bavi P, Beg S, Al Hazmi M, Al-Rasheed M, Alobaisi K, Al-Dayel F, AlManea H, Al-Sanea N, Uddin S, Al-Kuraya KS. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer 2014; 13: 168 [PMID: 25005754 DOI: 10.1186/1476-4598-13-168]
35. Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Med Oncol 2014; 31: 124 [PMID: 25073438 DOI: 10.1007/s12032-014-0124-3]
36. Tong JH, Lung RW, Sin FM, Law PP, Kang W, Chan AW, Ma BB, Mak TW, Ng SS, To KF. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther 2014; 15: 768-776 [PMID: 24642870 DOI: 10.4161/cbt.28550]
37. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 2014; 106: dju106 [PMID: 24925349 DOI: 10.1093/jnci/dju106]
38. Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin Cancer Res 2013; 19: 4104-4113 [PMID: 23741067 DOI: 10.1158/1078-0432.CCR-12-2581]
39. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18: 4753-4763 [PMID: 22753589 DOI: 10.1158/1078-0432.ccr-11-3210]
40. Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One 2013; 8: e81628 [PMID: 24339949 DOI: 10.1371/journal.pone.0081628]
41. Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q, Fu WL. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014; 9: e90607 [PMID: 24594804 DOI: 10.1371/journal.pone.0090607]
42. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120: 2316-2324 [PMID: 24737664 DOI: 10.1002/cncr.28729]
43. Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Golabek A, Coates T, Kopczynski J, Gozdz S, Miettinen M. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. Am J Surg Pathol 2014; 38: 1235-1241 [PMID: 24832158 DOI: 10.1097/pas.0000000000000229]
44. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854 [PMID: 22427238 DOI: 10.1038/bjc.2013.212]
45. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Öberg Å, Rutegård J, Palmqvist R. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 2013; 108: 2153-2163 [PMID: 23660947 DOI: 10.1097/DCR.0b013e31823c08b3]
46. Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, Yamamoto E, Kurokawa S, Adachi Y, Takahashi H, Okuda H, Kusumi T, Hosokawa M, Fujita M, Hasegawa T, Okita K, Hirata K, Suzuki H, Yamamoto H, Shinomura Y. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014; 35: 776-783 [PMID: 24242331 DOI: 10.1093/carcin/bgt374]
47. Omrane I, Kourda N, Stambouli N, Privat M, Medimegh I, Arfaoui A, Uhrhammer N, Bougatef K, Baroudi O, Bouzaienne H, Marrakchi R, Bignon YJ, Benammar-Elgaaied A. MicroRNAs 146a and 147b biomarkers for colorectal tumor's localization. Biomed Res Int 2014; 2014: 584852 [PMID: 24800242 DOI: 10.1155/2014/584852]
48. Gopalan V, Pillai S, Ebrahimi F, Salajegheh A, Lam TC, Le TK, Langsford N, Ho YH, Smith RA, Lam AK. Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance. Mol Carcinog 2014; 53 Suppl 1: E36-E44 [PMID: 24009195 DOI: 10.1002/mc.21993]
49. Maus MKH. Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum). 2013 ASCO Annual Meeting Abstract No: 3527 2013. J Clin Oncol 2013; 31 suppl: abstr 3527
50. Fecteau RE, Lutterbaugh J, Markowitz SD, Willis J, Guda K. GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PLoS One 2014; 9: e87966 [PMID: 24498230 DOI: 10.1371/journal.pone.0087966]
51. Freriksen JJ, Salomon J, Roelofs HM, Te Morsche RH, van der Stappen JW, Dura P, Witteman BJ, Lacko M, Peters WH. Genetic polymorphism 609C& gt; T in NAD(P)H: quinone oxidoreductase 1 enhances the risk of proximal colon cancer. J Hum Genet 2014; 59: 381-386 [PMID: 24830960 DOI: 10.1038/jhg.2014.38]
52. Ayiomamitis GD, Notas G, Zaravinos A, Zizi-Sermpetzoglou A, Georgiadou M, Sfakianaki O, Kouroumallis E. Differences in telomerase activity between colon and rectal cancer. Can J Surg 2014; 57: 199-208 [PMID: 24869613]
53. Kaprio T, Fermér C, Hagström J, Mustonen H, Böckelman C, Nilsson O, Haglund C. Podocalyxin is a marker of poor prognosis in colorectal cancer. BMC Cancer 2014; 14: 493 [PMID: 25004863 DOI: 10.1186/1471-2407-14-493]
54. Kim JH, Rhee YY, Kim KJ, Cho NY, Lee HS, Kang GH. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability. APMIS 2014; 122: 1187-1195 [PMID: 24909058 DOI: 10.1111/apm.12284]
55. Azzoni C, Bottarelli L, Cecchini S, Ziccarelli A, Campanini N, Bordi C, Sarli L, Silini EM. Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features. Pathol Res Pract 2014; 210: 111-117 [PMID: 24332575 DOI: 10.1016/j.prp.2013.11.004]
56. Bauer KM, Hummon AB, Buechler S. Right-side and left-side colon cancer follow different pathways to relapse. Mol Carcinog 2012; 51: 411-421 [PMID: 21656576 DOI: 10.1002/mc.20804]